U.S. wants at least $1 billion from drugmakers who delay generics
March 28, 2014 at 11:51 AM EDT
WASHINGTON, March 28 (Reuters) - The U.S. Federal Trade Commission seeks a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired, an FTC official told a legal conference on Friday.
